Edmonton, Alberta — January 13, 2026. Fedora Pharmaceuticals, Inc. announced plans to unveil the company’s lead candidate at the upcoming Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI). IMARI was launched in May 2025 by the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) as a forum for advancing the science of AMR.
It seems appropriate for Fedora to unveil its lead candidate — the first to be developed from a new class of antibiotic — at the inaugural IMARI conference. Fedora is not new to AMR drug development. In 2014, in partnership with Meiji Seika of Japan, we licensed a family of β-lactamase inhibitors to F. Hoffmann-La Roche for worldwide development.Christopher Micetich, CEO & Founder, Fedora Pharmaceuticals
During the conference, Fedora will present four posters outlining the mechanism, in vitro and in vivo activity, and resistance profile of the company’s first-in-class AMR candidate. IMARI is being held January 28–30, 2026, in Las Vegas, Nevada.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
